TG Therapeutics, Inc.

TGTX trades at a striking 14.1 P/E despite sitting at its 52-week high with an RSI of 76.1—a level typically signaling overbought conditions. The 23.48% short float suggests meaningful skepticism from bearish traders, yet the stock has powered higher anyway, implying strong conviction from longs. This combination of extreme momentum readings, elevated valuation relative to the broader pharma sector, and substantial short interest creates a precarious setup where any disappointment could trigger sharp reversals, though the conviction behind this move shouldn't be dismissed outright.